SOURCE: Medivation

Medivation

May 28, 2015 16:10 ET

Medivation Names Andrew Powell General Counsel

SAN FRANCISCO, CA--(Marketwired - May 28, 2015) - Medivation, Inc. (NASDAQ: MDVN) today announced the appointment of Andrew Powell as senior vice president, general counsel and corporate secretary, effective May 27, 2015. Andrew will serve as Medivation's chief legal officer, managing all of its legal affairs and reporting to David Hung, M.D., president and chief executive officer. He succeeds Jennifer Rhodes, who remains a member of the company's legal team.

"I am delighted to add an executive of Andrew Powell's experience and stature to Medivation's leadership team," said David Hung, M.D., president and chief executive officer of Medivation. "Andrew's blend of legal acumen and business savvy will serve us well as we continue pursuing our mission of developing innovative therapies for the treatment of serious diseases."

Andrew Powell added, "I am excited to be joining Medivation at this important point in its growth and development as an industry leader. I look forward to working with the rest of the Medivation team to build the XTANDI® (enzalutamide) franchise and pursue other important opportunities to improve the lives of patients and their families."

Mr. Powell brings to Medivation more than 25 years of leadership experience in the life sciences, most recently as executive vice president, general counsel and corporate secretary of InterMune, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune's acquisition by Swiss drug maker Roche for more than $8 billion. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology. Mr. Powell then served as senior vice president and general counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly. Immediately prior to joining InterMune, he was executive vice president, general counsel and secretary at Cornerstone Therapeutics through its successful sale to Chiesi Farmaceutici S.p.A.

Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School.

About Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com

Contact Information

  • Contact:
    Anne Bowdidge
    Sr. Director, Investor Relations
    (650) 218-6900